2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

5008 Identification of the gsh-GPX4 antioxidant response as a therapeutic vulnerability for TP53 mutant AML

A'ishah Bakayoko, Marisa Kruidenier2, Sarah Skuli, MD, PhD3, Martin Carroll, MD4
1 University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 University of Pennsylvania, Philadelphia, Pennsylvania, United States

Background: TP53-mutant (MT) acute myeloid leukemia (AML) carries a dismal prognosis, with only ~15% of patients surviving beyond 2 years. We previously demonstrated that TP53-MT AML cells survive treatment with standard AML chemotherapy agent, cytarabine (AraC), by limiting reactive oxygen species (ROS) accumulation through increased antioxidant production. Consistent with this mechanism, supplementation with the antioxidant glutathione (GSH) rescues AraC-induced ROS accumulation and cell death. Gene expression and metabolomic profiling following AraC treatment suggested that this adaptive antioxidant response is driven in part by increased activity of one-carbon metabolism (OCM), a central regulator of cellular redox homeostasis and GSH production. We also found that AraC induces the mevalonate pathway and that pharmacologic inhibition of this pathway with statins decreases total and reduced GSH, increases ROS, and sensitizes TP53-MT AML cells to AraC. Mevalonate-derived metabolites are required for the synthesis and activity of glutathione peroxidase 4 (GPX4), an enzyme that uses GSH to detoxify lipid peroxides and suppress ferroptosis. Altogether, this data suggests that OCM and the mevalonate pathway converge on a GSH–GPX4 antioxidant program that enables TP53-MT AML cells to survive AraC treatment. However, the specific OCM pathways required to sustain this antioxidant response—and whether their inhibition can enhance the efficacy of AraC and/or statins—remain unknown.

Methods: Initially, we have studied human AML cell line, MOLM14 cells in vitro. Cells have been engineered to be TP53 null or TP53 mutant as previously described (PMID: 40634510). Cells were treated with AraC, mevalonate pathway inhibitor, rosuvastatin, or inhibitors of OCM both alone and in combination.  We targeted each of the three branches of OCM, folate metabolism, the methionine cycle, and polyamine synthesis and salvage using a drug specific to a key enzyme in each of the branches. Survival was assessed using viable cell dyes by flow cytometry and GSH production was assessed using a GSH/GSSG-Glo luminescence assay. GPX4 expression was analyzed by Western blot.

Results: To identify OCM pathways that support therapeutic resistance, we selected 5-fluorouracil (5-FU) and methotrexate (MTX) to target the folate cycle, valproic acid (VA) to target the methionine cycle, and DFMO plus AMXT and DENSpm to target polyamine synthesis and salvage. Among these agents, MTX produced the strongest enhancement of AraC-induced cell death in TP53-MT AML cells, beyond its effect on cell viability as a single agent. Dose-response analysis demonstrated a significant interaction between MTX and AraC (adjusted p = 0.034 for TP53-MT AML), supporting increased sensitivity to AraC following DHFR inhibition. MTX also decreased viability when combined with rosuvastatin or with AraC plus rosuvastatin; however, significant enhancement beyond the effects of the individual agents was not detected in these treatment groups. The absence of a comparable effect with 5-FU suggests that the phenotype is not shared by all inhibitors of folate metabolism and may reflect a specific requirement for dihydrofolate reductase (DHFR) activity.

To determine whether the effect of MTX was associated with impaired antioxidant capacity, we measured total and reduced GSH following treatment with MTX (0.1 µM, 48 hours), rosuvastatin (50 µM, 48 hours), and/or AraC (1 µM, 24 hours). MTX reduced GSH and was similarly as effective as rosuvastatin in preventing the increase in GSH induced by AraC. Because GPX4 uses GSH to detoxify lipid peroxides, we next evaluated GPX4 expression. AraC increased GPX4 expression in TP53-MT AML cells, whereas cotreatment with either MTX or rosuvastatin attenuated this induction.

Conclusion: These studies identify DHFR-dependent folate metabolism as a regulator of AraC resistance in TP53-MT AML. MTX reduces GSH production, prevents AraC-induced increases in GSH and GPX4, and significantly enhances the cytotoxic activity of AraC. Collectively, these findings support a model in which folate and mevalonate metabolism converge on a GSH–GPX4 antioxidant program that protects TP53-MT AML cells from AraC-induced oxidative stress. They further nominate DHFR inhibition as a clinically actionable strategy for disrupting this adaptive response and enhancing AraC efficacy.
A'ishah Bakayoko: No relevant conflicts of interest to declare.